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We have evaluated protection against a genital Chlamydia trachomatis infection in a pig 
challenge model. Protection was promoted by the porcine granulocyte macrophage-colony 
stimulating factor (GM-CSF), the Escherichia coli thermo-labile enterotoxin LT as an 
exceptionally potent mucosa-binding molecule and by a major outer membrane protein (MOMP)-
based DNA vaccine carrying CpG motifs incorporated in the plasmid backbone. Protection 
achieved by mucosal (vaginal and nasal) immunization will be compared to systemic 
(intradermal) immunization. We could demonstrate that mucosal administration leads to 
significant protection against genital C. trachomatis challenge as significantly less severe 
macroscopic lesions, less chlamydial shedding and replication in the urogenital tract was 
demonstrated in the vaccinated animals. Also, significantly higher proliferative responses of 
peripheral blood lymphocytes were observed. Furthermore, the combination of nasal and vaginal 
immunization could induce serum antibody titers upon immunization and early upon challenge 
with C. trachomatis serovar E. However, the infection could not be eradicated. Systemic 
immunization was significantly less efficient at eliciting protection, which emphasizes the need 
for a mucosal vaccine in order to obtain significant protection against genital C. trachomatis 
infection.  
